Indoor Biotechnologies is pleased to have served the allergen diagnostic industry over 10 years. Using our proven expertise in structural biology and protein expression, Indoor Biotechnologies has designed and created a comprehensive portfolio of allergen components for diagnostic use, including dust mite, animal, food, mold, pollen, cockroach, venom and other allergens.
, a technological breakthrough that is poised to make a significant impact on diagnostic applications. The human IgE monoclonal antibodies are are derived from allergic patients with a clinical history of allergic disease and an excellent alternative to allergic-sera for diagnostic purposes.
Contact Beattie Sturgill to discuss business opportunities in allergy and in other biologics systems.
InBio® Allergen Pipeline 2021
As part of the molecular approach to allergen diagnostics, Indoor Biotechnologies is rapidly expanding its portfolio of allergen components. This year’s R&D efforts will focus on a variety of food, animal and pollen allergens. Plan ahead with the Allergen Pipeline 2021
Human IgE Monoclonal Antibodies Unique and Exclusive* Product to InBio®
Indoor Biotechnologies’ initial panel consists of 15 IgE monoclonal antibodies to major inhaled and food allergens from dust mite, cat, dog, egg, peanut, cashew, and walnut. Applications include:
QC and validation of purified allergens for molecular diagnostics
In vitro IgE diagnostic tests, calibrators, controls, alternatives to human sera
Molecular reference standards for IgE
Epitope analysis and localization of IgE epitopes
Mast cell/basophil activation assays and histamine release
Animal models of anaphylaxis
*Indoor Biotechnologies has signed a license agreement with Vanderbilt University for human IgE monoclonal antibody technology. Under this agreement, Indoor Biotechnologies has worldwide, exclusive rights to commercialize the IgE monoclonal antibodies developed at Vanderbilt University Medical Center (VUMC) for research and diagnostic use.